Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 10/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.58 |
| ▸ | HTR5A | P47898 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8807086 | 0.97 | ABCB1 (0.71) | ABCB1MAOBMAOAABCG2ABCC1 | |
| SCHEMBL8789776 | 0.87 | ABCB1 (0.65) | ABCB1MAOBMAOAABCC1TMEM97 | |
| SCHEMBL8790224 | 0.85 | ABCB1 (0.62) | ABCB1MAOBMAOAABCC1TMEM97 | |
| SCHEMBL8791612 | 0.85 | ABCB1 (0.58) | ABCB1ABCG2TMEM97 | |
| SCHEMBL8790054 | 0.85 | ABCB1 (0.71) | ABCB1ABCG2ABCC1TMEM97 | |
| SCHEMBL17664978 | 0.84 | ABCB1 (0.69) | ABCB1ABCG2 | |
| SCHEMBL8789531 | 0.83 | ABCB1 (0.81) | ABCB1ABCG2 | |
| SCHEMBL8789322 | 0.83 | HTR5A (0.67) | MAOBMAOAHTR5ATDP1HRH3 | |
| SCHEMBL8789885 | 0.83 | ABCB1 (0.78) | ABCB1MAOBMAOAABCG2ABCC1 | |
| SCHEMBL7256134 | 0.83 | ABCB1 (0.78) | ABCB1MAOBMAOAABCC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |